INTRODUCTION {#s1}
============

We previously showed that 3^rd^ party, *ex-vivo* expanded, umbilical cord blood (UCB) Treg cells can prevent graft versus host disease (GVHD) in xenogenic mouse model \[[@R1]\]. Additionally, efficacy of cultured UCB Tregs improves when incubated with fucosyltransferase-VI enzyme, which establishes Siayl-Lewis X moiety on P-selectin \[[@R2]\]. We hypothesized that adoptive therapy with fucosylated UCB Tregs would prevent GVHD and conducted a pilot clinical trial (<https://www.clinicaltrials.gov> NCT02423915). We report preliminary safety data in 5 patients undergoing allogeneic stem cell transplant (AlloSCT) (Double UCB Transplant (dUCBT)= 2; Peripheral Blood (PB) Matched Unrelated Donor Transplant (MUD) = 3) who received UCB Tregs at dose: 1×10^6^ cells/kg (Fucosylated UCB Tregs = 3; Non-Fucosylated UCB Tregs = 2) that were matched at least at HLA 3/6 to recipient.

RESULTS {#s2}
=======

Graft and UCB Treg characteristics {#s2_1}
----------------------------------

Five patients were treated at UCB Treg dose level: 1×10^6^ cells/kg; 2 patients received non-fucosylated UCB Tregs followed by dUCB AlloSCT and 3 patients received fucosylated UCB Tregs followed by PB MUD AlloSCT. Donor graft and UCB Treg characteristics are shown in Table [1](#T1){ref-type="table"}. All patients received designated UCB Treg dose: 1×10^6^ cells/kg (1.16×10^6^/kg ±0.05) and purity of UCB Treg product (phenotype:CD4^+^25^+^127^lo^) at the time of release and infusion on day 14 of expansion was 90% (range, 86-93%). UCB units identified for Treg manufacture had median of 9.6×10^8^ TNCs (range, 9.1-11.4×10^8^ TNCs) with a median fold expansion of 71-fold (range, 42-80-fold) at day 14 of culture.

###### Donor graft and UCB Treg characteristics

  ---------------------------------------------------------------------------------------------------------------------------------
                                                     Patient 1           Patient 2           Patient 3    Patient 4    Patient 5
  -------------------------------------------------- ------------------- ------------------- ------------ ------------ ------------
  Day 0\                                             25                  8.3                 12           22           15.5
  CD25^+^ (10^6^)                                                                                                      

  Day 0\                                             70                  90                  96           83           96
  CD25^+^ Purity (%)                                                                                                   

  Day 14\                                            1492                352                 857          1267         1242
  TNC (10^6^)                                                                                                          

  Day 14\                                            60                  42                  71           58           80
  Fold Expansion                                                                                                       

  Day 14\                                            86                  92                  93           88           90
  % Treg                                                                                                               

  Day 14\                                            N/A                 N/A                 3.35         3.5          4.46
  Pre-Fucosylation CLA (%)                                                                                             

  Day 14\                                            N/A                 N/A                 84.8         79.6         74.7
  Post-Fucosylation CLA (%)                                                                                            

  CB Treg cell dose\                                 1.2                 1.19                1.1          1.2          1.1
  (1×10^6^ cells/kg)                                                                                                   

  UCB Treg HLA Matching to Recipient                 4 out of 6          4 out of 6          5 out of 6   5 out of 6   5 out of 6

  Donor Graft HLA Matching to Recipient              CB 1: 4 out of 6\   CB 1: 5 out of 6\   6 out of 6   6 out of 6   6 out of 6
                                                     CB 2: 4 out of 6    CB 2: 5 out of 6                              

  Donor total infused cell dose (1×10^6^ cells/kg)   64.29\              36.95\              1486.25      635.21       2008.61
                                                     (CB\#1: 41.27\      (CB\#1: 21.88\                                
                                                     CB\#2: 23.02)       CB\#2: 15.07)                                 

  Donor T cell dose (CD3^+^)\                        28.69\              14.77\              391.70       158.41       371.19
  (1×10^6^ cells/kg)                                 (CB\#1: 19.04\      (CB\#1: 6.74\                                 
                                                     CB\#2: 9.65)        CB\#2: 8.03)                                  

  Ratio of\                                          24                  12                  356          132          337
  Donor Tcon: UCB Treg                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------

Figure [1A](#F1){ref-type="fig"} is a representative of UCB Treg phenotype where far right panels demonstrates CLA expression at Day 14. Figure [1C](#F1){ref-type="fig"} demonstrates suppressive activity of representative UCB Treg clinical product harvested at Day 14 where the cells maintained significant (\>85%) suppressor function. In all patients the ratio of donor T-cells was at least 12 times higher than infused UCB Tregs. Patients did not experience any infusion reaction due to UCB Tregs.

![Characterization of clinical *ex-vivo* expanded CB Tregs\
**(A)** Representative flow cytometry analysis of CB Tregs. Top row is Day 0 isolation of CD25 cells. Bottom row is Day 14 expanded Tregs. Far right panels: CLA expression at Day 14 Pre- (top) and Post- (bottom) fucosylation. **(B)** Total expanded viable cells counted at each time point in culture. Results are mean ± SEM. **(C)** Representative flow plots of Treg:Tcon suppression assay from *ex vivo* expanded CB Tregs.](oncotarget-09-35611-g001){#F1}

Patient characteristics (Table [2](#T2){ref-type="table"}) {#s2_2}
----------------------------------------------------------

### Patient 1 {#s2_2_1}

59 yo female with FLT3 positive AML, status post induction therapy with cladribine/idarubicin/Ara-C/Sorafenib, underwent dUCBT with conditioning regimen: Flu/Cy/TBI +UCB Tregs at dose: 1×10^6^ cells/kg on day −1 and donor cells on day 0; where ratio of Treg:Tcon was 1:24. Neutrophils engrafted Day 14 and platelets on Day 27 with 100% donor chimerism at day 30. On day +25, grade II acute GVHD in the lower gastrointestinal tract (GI) (only) was recorded. Duodenal biopsy immunohistochemistry (IHC) of FOXP3 revealed Treg clustering around areas of GVHD, with occasional exocytosis into epithelial structures (Figure [2C-A](#F2){ref-type="fig"}). Similar Treg infiltration was also seen in the colonic biopsy (Figure [2C-B](#F2){ref-type="fig"}). Although initial episode of GVHD resolved with steroids by day 69, GVHD relapsed at day 322 requiring systemic steroids and oral Ruxolitinib. At last follow up, 32 months months from transplant, patient was alive, disease free, and off immune-suppression.

###### Patient characteristics and outcomes

  --------------------------------------------------------------------------------------------------------------------------------------------------------
                                                Patient 1                Patient 2           Patient 3          Patient 4         Patient 5
  --------------------------------------------- ------------------------ ------------------- ------------------ ----------------- ------------------------
  Age (yrs)                                     59                       58                  51                 65                34

  Gender (M/F)                                  F                        M                   M                  M                 M

  Diagnosis                                     Acute Myeloid Leukemia   Mycosis Fungoides   Multiple Myeloma   Myeloid sarcoma   Acute Myeloid Leukemia

  Conditioning regimen^\*^                      Flu/Cy/TBI               Flu/Cy/TBI          Flu/Mel140         Flu/Mel140        Flu/Mel140

  Transplant\                                   Double cord              Double cord         PB MUD             PB MUD            PB MUD
  Type                                                                                                                            

  Infusion reaction (Y/N)                       N                        N                   N                  N                 N

  Time to Engraftment Neutrophil (Days)^\*\*^   14                       17                  10                 11                8

  Time to Engraftment Platelets (Days)^\*\*^    27                       N/A                 11                 12                10

  D30 donor Chimerism (%)                       100                      62                  100                100               100

  Acute GVHD\                                   Y                        N                   Y                  Y                 Y
  (Y/N)                                                                                                                           

  aGVHD\                                        II                       0                   II                 IV                II
  grade                                                                                                                           

  aGVHD\                                        GI                       N/A                 Liver              Skin              Skin
  site                                                                                                                            

  Time to aGVHD (Days)^\*\*^                    25                       N/A                 19                 40                19

  aGVHD resolution at Day 180                   Y                        N/A                 Y                  Y                 Y

  Time to aGVHD resolution (Days)^\*\*^         69                       N/A                 40                 130               124

  Alive\                                        Y                        N                   Y                  Y                 Y
  (Y/N)                                                                                                                           

  Last Follow up (Days)^\*\*^                   960\                     45\                 780\               720\              660\
                                                (32 months)              (1.5 months)        (26 months)        (24 months)       (22 months)

  Relapse GVHD                                  Y                        N/A                 N                  N                 N

  Time to GVHD Relapse                          322                      N/A                 N/A                N/A               N/A

  Disease Relapse                               N                        N                   N                  N                 N

  Disease Response                              CR                       N/A                 CR                 CR                CR

  Chronic GVHD                                  N                        N/A                 N                  N                 N
  --------------------------------------------------------------------------------------------------------------------------------------------------------

^\*^Flu/Cy/TBI: Fludarabine 40 mg/M2 IV (D-8 to D-5), cyclophosphamide 50 mg/kg plus Mesna D-6, Total body radiation 2Gy D-4; Flu/Mel140: Fludarabine 40 mg/M2 IV (D-5 to D-2); Melphalan 140 mg/M2 IV D-2.

^\*\*^All days calculated from the day of transplant.

![Patient outcomes\
**(A)** Cumulative Incidence: ANC (Absolute Neutrophil Count) and Platelet engraftment. **(B)** Overall Survival. **(C)** FOXP3 immunohistochemistry showing Treg infiltration in tissue samples with graft-versus-host disease (GVHD). (A) Treg cells in a duodenal biopsy showing clustering around areas of epithelial distortion by GVHD (inset; thin arrow). Higher power shows exocytosis of Tregs into glandular epithelium (thick arrow). (B) Similar findings were seen in a colonic biopsy. \[A: 40x (inset 20x); B: 40x\].](oncotarget-09-35611-g002){#F2}

### Patient 2 {#s2_2_2}

58 yo male with mycosis fungoides/Sezary syndrome, multiple lines of treatment including methotrexate, soriatane, intramuscular steroids, adalimumab and extracorporeal photopheresis with subsequent development of leptomeningeal disease and right temporal lobe lymphoma, status post 7 cycles of high dose methotrexate and one cycle of high dose arabinoside with resolution of brain disease. Due to persistent active nodal disease, patient underwent one cycle of CEOP (cyclophosphamide, etoposide, prednisolone and vincristine) and received dUCBT using conditioning regimen: Flu/Cy/TBI + UCB Tregs at dose: 1×10^6^ cells/kg on day −1 and donor cells on day 0; where the ratio of Treg:Tcon was 1:12. Patient engrafted neutrophils on day 17 and had 62% chimerism on day 30. Patient did not develop GVHD but died of brain hemorrhage on day 45.

### Patient 3 {#s2_2_3}

51 yo male with relapsed/refractory kappa light chain multiple myeloma status post at least 7 lines of treatment including two autologous stem cell transplant, underwent PB MUD AlloSCT using conditioning regimen: Flu/Mel + fucosylated UCB Tregs at dose: 1×10^6^ cells/kg on day −1 and donor cells on day 0; where the ratio of Treg:Tcon was 1:356. Patient developed high fevers and rash on day 5 that resolved with high dose steroids (1 mg/kg). Neutrophils engrafted on Day 10 and platelets on Day 11 with 100% donor chimerism at day 30. On day +19, grade II acute GVHD of liver (only) was reported based on biopsy result which resolved with systemic steroids by day 40 and did not require second line therapy. Patient did not have recurrence of GVHD. At last follow up, 26 months from transplant, patient was alive, free of myeloma, without GVHD and off immunesuppressors. No evidence of chronic GVHD.

### Patient 4 {#s2_2_4}

65 yo male with FLT3 positive myeloid sarcoma status post 3 cycles of FLAG-IDA underwent PB MUD AlloSCT using conditioning regimen: Flu/Mel + 3^rd^ party fucosylated UCB Tregs at dose: 1×10^6^ cells/kg on day −1 and donor cells on day 0; where the ratio of Treg:Tcon was 1:132. Patient developed high fever and rash on day 6 that resolved with high dose steroids (1 mg/kg). Patient engrafted neutrophils on day 11 and platelets on day 12 with 100% donor chimerism at day 30. On day +40, grade IV acute GVHD of skin (only) was reported on biopsy result which required treatment with systemic steroids, extra corporeal photopheresis and Ruxolitinib and resolved by day 130. At last follow up, 24 months from transplant, patient was alive, disease free, without GVHD and off immune-suppression. No evidence of chronic GVHD.

### Patient 5 {#s2_2_5}

34 yo male with AML with high risk cytogenetics status post Ida/Ara-C induction and 3 cycles of high dose Ara-C, underwent PB MUD AlloSCT with conditioning: Flu/Mel +fucosylated UCB Tregs at a dose: 1×10^6^ cells/kg on day −1 and donor cells on day 0; where the ratio of Treg:Tcon was 1:337. Patient developed high fever and rash on day 5 that resolved with high dose steroids (1 mg/kg). Patient engrafted neutrophils on day 8 and platelets on day 10 with 100% donor chimerism at day 30. On day +19, grade II acute GVHD of skin (only) was reported based on biopsy result which resolved with systemic steroids. Patient was intolerant of steroids and was switched to oral Ruxolitinib, resolving GVHD by day 124. At last follow up, 22 months from transplant, patient was alive, disease free, without GVHD and off immune-suppression. No evidence of chronic GVHD.

Survival data {#s2_3}
-------------

At a median follow up of 25 months (range 1.5-32 months) there were no disease relapse and overall survival was 80% (Figure [2B](#F2){ref-type="fig"}).

Correlative assay {#s2_4}
-----------------

### Flow cytometry {#s2_5_1}

Circulating Tregs showed a concurrent bimodal increase (Day 1, 21) (Figure [3A](#F3){ref-type="fig"}). IL-10 secreting Tregs were detected at early time points (Day 0,1) with significant increases at Day 7 before subsiding (Figure [3B](#F3){ref-type="fig"}) while bimodal increase in IL-10 plasma levels occurred at Day 7 and 21 (Figure [3C](#F3){ref-type="fig"}). No significant changes were observed in naïve T cells and either central or effector memory T-cells, however T-effector (Teff) cell fraction (CD45RA^−^CD45RO^+^CCR7^−^CD62L^−^) increased above normal starting at Day 7 (Figure [3D](#F3){ref-type="fig"}), resembling a Th1 IFN-γ secreting population with minimal Th2 (IL4) and Th17 (IL-17) populations at early time points (Figure [3E](#F3){ref-type="fig"}), as evident by higher plasma levels of IFN-γ when compared to IL-17(Figure [3F](#F3){ref-type="fig"}). An increase in NK cells, CD3^−^CD56^+^CD16^+^, was also observed beginning at Day 7 (Figure [3G](#F3){ref-type="fig"}) that correlated with elevated IL-15 plasma levels detected in early post-transplantation period (Figure [3H](#F3){ref-type="fig"}). No statistically relevant increases in dendritic cells or lineage B cells were noted. Extensive immune reconstitution panel is shown in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}.

![Hematopoietic analysis of patient peripheral blood\
**(A)** Flow cytometric analysis of number of Tregs (CD4+CD25+CD127-). **(B)** Flow cytometric analysis of percent IL-10 secreting cells in PB. **(C)** Plasma analysis of IL-10 in PB. **(D)** Flow cytometric analysis of T effector cells (RA-RO+CD62L-CCR7-) in PB. **(E-F)** Analysis of Th1 (IFN-γ), Th2 (IL-4), Th17 (IL-17) secreting cell populations using either flow cytometry (E) or Luminex (F). **(G)** Flow cytometric analysis of NK cells in patient PB (CD3-CD56+). **(H)** Plasma analysis of IL-15 in patient PB.](oncotarget-09-35611-g003){#F3}

### Cytokine assay {#s2_6_1}

Notably, plasma IL-2 dropped in all patients at Day 7 (Figure [4A](#F4){ref-type="fig"}), whereas, IL-6 and IL-8, both pro-inflammatory cytokines, peaked at Day 7 before decreasing and falling to normal levels at Day 14 (Figure [4B, 4C](#F4){ref-type="fig"}). While various biomarkers of GVHD were screened, only ST-2, OPN and Follistatin showed elevated levels beginning at Day 7 (Figure [4D, 4E, 4F](#F4){ref-type="fig"}). Extensive analysis of patient serum is shown in [Supplementary Figure 2](#SD1){ref-type="supplementary-material"} (chemokines and growth factors) and [Supplementary Figure 3](#SD1){ref-type="supplementary-material"} (cytokines and soluble factors and receptors).

![Analysis of GVHD in patient plasma\
Plasma analysis of inflammatory cytokines IL-2. **(A)** IL-6 **(B)** and IL-8 **(C)** in patient PB. Analysis of GVHD biomarkers ST-2 **(D)**, osteopontin **(E)** and follistatin **(F)** in patient PB. **(G-H)** ELISA analysis of REG3a and Elafin in plasma of patient PB.](oncotarget-09-35611-g004){#F4}

### Reg3a and elafin assay {#s2_7_1}

Two factors, Reg3a and Elafin, have recently been used as biomarkers of GVHD suggesting involvement in chronic GVHD \[[@R3]\]. Only in PB MUD AlloSCT recipients, the Reg3a slowly increased in the post-transplant period, peaking at Day 14 before subsiding to normal levels (Figure [4G](#F4){ref-type="fig"}), whereas, Elafin increased later at Days 21-30, before decreasing (Figure [4H](#F4){ref-type="fig"}). The late increase in the Reg3a and Elafin level in Patient no. 4 was not associated with GVHD relapse or infection. Similarly, no rebound increase was seen in Patient no. 1 who did suffer GI GVHD relapse.

DISCUSSION {#s3}
==========

We are the first to show safety and feasibility of infusion of 3^rd^ party, *ex vivo* expanded, fucosylated UCB Treg cells in patients undergoing PB MUD AlloSCT. We had to conduct the study with a low dose of UCB Tregs at 1×10^6^ cells/kg when safety with higher dose has been published by Brunstein et al. \[[@R4], [@R5]\] due to the recommendation of MDACC safety board, since this was the first time UCB Treg cell product was manufactured at the MDACC GMP facility and the first time UCB underwent fucosylation for clinical use. We understand that with a small sample size with heterogenous characteristics, it is hard to make any concrete dervations, but we can certainly conclude that the UCB Treg infusions were safe without any detrimental effect on the patients. Similarly the different diagnoses and the variable graft characteristics may impact the clinical course and immune reconstitution differently and may prohibit from a conclusive finding. The high variability in the donor T cell: UCB Tregs of 12-356 remained a function of the donor graft characteristics, specifically the low count derived from double cord transplant as compared to the high count reflected in the peripheral blood transplant. Overall, the dose level: 1.0 × 10^6^ cells/kg was well-tolerated with no infusional toxicity or impact on engraftment. Specific presentation of high fevers associated with non-specific inflammatory rash and elevated IL-6 levels in the post-transplant period of patients receiving fucosylated UCB Tregs may be consistent with pre-engraftment syndrome \[[@R6], [@R7]\]. It is unclear whether the short course of systemic steroids impacted efficacy of infused UCB Tregs, since all patients developed GVHD, however, it is important to consider that the infused donor T cells were significantly higher (12-356 times) than the infused Tregs. Since published clinical data has shown that a higher ratio of Tregs to Tcons is needed for effective prevention of GVHD, we did not expect complete abrogation of GVHD with such a low dose of Tregs. Brunstein et al \[[@R4], [@R5]\] showed that at least 10 times higher UCB Tregs than Tcons results in decreasing the grade II-IV aGVHD rate to 9% as compared to 45% in controls. Similarly, at least 2 times higher donor Tregs than donor Tcons are needed in the absence of post-transplant immune-suppression in a haplo-transplant setting to result in acute GVHD rate of 15% \[[@R8], [@R9]\] as compared to 24% in those receiving T-cell replete haplo-transplant \[[@R10]\].

As compared to published data where only a third of patients with grade ≥2 GVHD show durable response to first line therapy \[[@R11]\], in our small sample size, all patients underwent resolution of their GVHD symptoms and were off immune-suppression at a median follow up of 25 months. It is unclear as to why only patient no. 1 developed relapse of GI GVHD and future studies may help us understand whether there is correlation with her high risk AML vs. dietary habits vs. immune reconstitution. At this time we don\'t have a clear explanation. It is also unclear as to why patient no. 4 who developed steroid refractory grade 4 skin only GVHD at Day +60 requiring photopheresis and oral Ruxolitnib then underwent complete resolution and at 20 months post-transplant, demonstrates no evidence of GVHD with no need for continued immune suppression and remains free of his high risk leukemia. This is notable considering that patients with steroid refractory grade 4 skin GVHD have been reported to have high treatment related mortality \[[@R12]\] Again, larger cohort of patients will allow for valuable insights into the immune reconstitution and may unravel novel mechanisms of GVHD pathogenesis and resolution.

In fact, four out of five patients with high risk disease are alive at a median follow up of 25 months. A recent meta-analysis of fourteen eligible studies where high levels of Tregs in donor grafts were associated with improved OS, a significant reduction in non-relapse mortality and a reduced risk of acute GVHD \[[@R13]\] and supports our findings. Haplo-transplant recipients with high risk leukemia who received adoptive therapy with donor Tregs without post-transplant immune-suppression also showed low risk of relapse of \<5% at 3 year follow up \[[@R8], [@R9]\].

In our report, all patients showed robust immune reconstitution. Infused UCB Tregs are most likely responsible for initial rise in circulating Tregs followed by a second peak due to proliferation of Tregs in response to effector T-cell expansion. Parallel decrease in plasma IL-2 level correlates with expansion of Treg compartment in early post-transplant period, while increase in IL-6 and IL-8 may represent post-transplant inflammatory environment especially in patients with high fever and rash \[[@R14]\]. While increases in IFN-γ secreting cells (Th1) might have also followed initial expansion of T-cell compartment, conflicting data exists for role of IFN-γ both in promoting and inhibiting GVHD \[[@R15]\].

We noted an increase in some GVHD biomarkers including ST2, OPN and Follistatin \[[@R16]--[@R20]\] approximately at Day +7, correlating with subsequent development of GVHD. We utilized the algorithm developed by Hartwell *et al.* where concentrations of two biomarkers (ST2 and REG3a) at 7 days post AlloSCT, predicted patients at high risk for lethal GVHD and non-relapse mortality \[[@R3]\]. In our patients normal values of REGa/Elafin at day 7 correlated with lack of chronic GVHD. With enrollment of additional patients in this trial, we will be able to further ascertain the predictive role of such biomarkers.

Although, our study consisted of only 5 patients, the long term follow up of the 4 alive patients who exhibited no infusion reaction or long term complication from UCB Treg infusion and who remain in disease remission and off immune-suppression underscores the promise of cell therapy such as UCB Tregs in the continued improvement of the outcomes of AlloSCT. The next cohort will enroll 10 patients undergoing AlloSCT and will receive non-fucosylated UCB Tregs at dose level: 1×10^7^cells/kg. In this cohort, we will plan to primarily include the PB MUD transplant graft in order to make an attempt to keep the donor T cell: UCB Treg ratio consistent and continue to perform immune reconstitution at the close data points in the post-transplant recovery period. At the time of submitting this manuscript, we have already treated one patient undergoing PB MUD for CML Blast crises with the higher dose of UCB Treg at 1×10^7^cells/kg and at a follow up of 1.5 years, we have observed no evidence of GVHD or leukemia relapse (data not shown). We believe that 3^rd^ party UCB derived Treg therapy holds the promise to be an effective strategy to improve overall outcomes of AlloSCT and additional studies have to be performed to determine the optimal dose.

MATERIALS AND METHODS {#s4}
=====================

Treatment and supportive care {#s4_1}
-----------------------------

The protocol was approved by the Institutional Review Board of University of Texas MD Anderson Cancer Center and registered at <https://www.clinicaltrials.gov> as NCT02423915. All patients provided written informed consent. Treatment details are shown in Table [2](#T2){ref-type="table"}. GVHD prophylaxis included mycophenolate-mofetil 1.5 gram intravenously (IV) or orally (PO) twice daily from day −3 to +30 in combination with oral sirolimus with loading dose of 12 mg followed by 4 mg daily and target through level between 3-12 ug/mL from day −3 to day +100. Supportive care was followed as per institutional guidelines. Diagnosis of acute GVHD was made within 100 days of transplant and chronic GVHD thereafter \[[@R21]\]. GVHD diagnosis was based on patient presentation of acute diarrhea, rash and/or liver function abnormalities followed by tissue biopsy.

Study objectives {#s4_2}
----------------

### Primary objective {#s4_3_1}

Determine safety of administering fucosylated and non-fucosylated UCB Tregs in AlloSCT setting.

### Secondary objectives {#s4_4_1}

Estimate probabilities of Grade II-IV GVHD; Engraftment; Relapse incidence and survival.

### Patient inclusion criteria {#s4_5_1}

i\) High risk hematologic malignancies; ii) availability of matched related donor (MRD) or MUD source or UCB unit(s) available for the primary transplant., iii) Age ≥16 and ≤80 years, iv) Bilirubin ≤1.5 mg/dl, SGPT ≤200 IU/ml (unless Gilbert\'s syndrome), v) Creatinine clearance of \>50 mL/min, vi) Diffusing capacity for carbon monoxide ≥45%, vii) Left ventricular ejection fraction ≥40%, vii) Zubrod performance status ≤2 \[[@R22]\]), viii) Twenty-one or more days since patient\'s last radiation or chemotherapy administration before beginning treatment for AlloSCT.

### Patient exclusion criteria {#s4_6_1}

i\) HIV seropositivity, ii) Uncontrolled infection, iii) Pregnancy.

UCB Treg manufacture {#s4_7}
--------------------

UCB Tregs were manufactured as described previously \[[@R1]\]. Cryopreserved UCB units matched at HLA 3/6 to recipient were provided by MDACC UCB bank. Units were thawed and processed in CliniMACS buffer (Miltenyi Biotec, Bergish Gladbach, Germany) containing 0.5% HSA (Baxter Healthcare, Westlake Village, CA. USA) and mono-nuclear cells selected for CD25^+^ using magnetic beads according to manufacturer\'s instructions (Miltenyi Biotec, Bergish Gladbach, Germany) \[[@R23]\]. CD25^+^ cells were co-cultured with CD3/28 co-expressing Dynabeads® (Clin *Ex Vivo* ™ CD3/CD28, Invitrogen, Carlsbad, CA) at 1:1 cell:bead ratio and seeded at 1×10^6^ cells/ml in *EX-VIVO* 15 medium (Cambrex BioScience, Walkersville, MD) supplemented with 10% human AB serum (Gemini Bio-Products, Sacramento, CA), 2 mM L-glutamine (Sigma, St. Louis, MO), 1% Penicillin-Streptomycin (Gibco/Invitrogen, Grand Island, NY)\] and 1000 IU/ml interleukin (IL)-2 (CHIRON Corporation, Emeryville, CA). Cells were cultured in tissue culture flasks at 37°C/5% CO~2~ incubator and maintained at 1×10^6^ cells/ml with fresh medium and IL-2 every 48-72 hours. Culture was harvested at 14 days. Release criteria included: Viability ≥70%, Endotoxin \<5EU/kg, Gram Stain: No organism seen, Mycoplasma: Negative, Sterility: No organism at time of infusion, CD4^−^CD8^+^ cells: \<10 %, CD4^+^CD25^+^ cells \>60% and \<100 beads per 3×10^6^ cells.

*Ex-vivo* fucosylation {#s4_8}
----------------------

Harvested UCB Treg cells were incubated in fucosylation solution (1/25 dilution of fucosyltransferase enzyme (FTVI) provided by Targazyme Inc. (Carlsbad, CA) in 1 mM GDP Fucose, phosphate-buffered saline 1% HSA) for 30 minutes at room temperature.

Flow cytometry {#s4_9}
--------------

*Ex vivo* expanded UCB Tregs were analyzed for CD45/CD4/CD8/CD25/CD127 and cutaneous lymphocyte antigen (CLA/HECA-452) expression. Patient PB were obtained at baseline, Day −1, 0, 1, 3, 7, 14, 21, 30, 60 and 90. Analysis was performed using the following markers: a) T-cells: CD45RO/CD45RA/CD127/CD62L/CD3/CD4/CD8/CCR7; b) B-cells: CD19/IgM/CD27/CD24/CD38; c) Dendritic cells: CD123 (plasmacytoid DC), CD11c (myeloid DC); d) Natural Killer (NK) cells: CD3-CD56+CD16+ (NK); CD3+CD56+CD16+ (NKT).

To assay for cytokine-expressing T cell subsets, thawed cells were rested overnight then activated for 5 hours with Cell Stimulation Cocktail (ThermoFisher, Waltham, MA. USA) and stained for Th1/Th2/Th17/Treg subsets using IFN-γ/IL4/IL-17/IL-10 antibodies respectively. Antibodies were obtained from either BD Biosciences (San Jose, CA) or eBioscience (ThermoFisher). Cells were acquired on an LSR Fortessa (BD Bioscience) and analyzed using FlowJo software (FlowJo, Ashland, OR. USA).

Suppression assays {#s4_10}
------------------

Conventional T cells (Tcon cells, CD4^+^CD25^−^) were stained with CellTrace Violet (Invitrogen, Carlsbad, CA) following manufacturer\'s recommendations and stimulated with 1:1 CD3/28 beads (Invitrogen, Carlsbad, CA) at 50,000 cells/well of a 96-well plate, in presence of Tregs at a different ratios; and then incubated for three days at 37°C followed by assessment of Tcon-proliferation using LSR Fortessa and analyzed using FlowJo software.

Cytokine array {#s4_11}
--------------

Cytokine analyses were performed using multiplex immuno-assay platform (Luminex, Austin, TX). Measurements were performed in undiluted samples, except for EPO-R (1:10) and E-Selectin, Elastase, Granzyme B, CCL28, and SDF1a (1:100). Heterblock (Omega Biologicals, Bozeman, MT) was used to prevent interference from heterophilic antibodies. Data were analyzed by 5-parametric curve fitting using Bio-Plex Manager software, version 6.1 (Bio-Rad, Hercules, CA). Multiplex immunoassays were in-house validated and show an intra- and inter-assay variability of \<5% and 20%, respectively, and recovery values of spikes proteins in serum of 95--105%.

Reg3a and elafin {#s4_12}
----------------

Elisa kits were obtained for Reg3a and Elafin from R&D Systems (Minneapolis, MN). Elisa was performed following manufacturer\'s instructions. Plasma samples from patients were diluted 1:1200 prior to evaluation and standard curve was utilized to properly determine levels of factors within the plasma. Elisa was analyzed using an Epoch Microplate Spectrophotometer (Biotek, Winooski, VT).

Immunohistochemistry {#s4_13}
--------------------

Immunohistochemistry (IHC) was performed on automated Leica Bond immunostainers (Leica Biosystems, Buffalo Gove, IL,) as described previously \[[@R6]\]. Briefly, formalin-fixed paraffin-embedded tissue sections cut at 4-5 μm thickness were de-paraffinized and subjected to antigen retrieval prior to incubation with an anti-FOXP3 monoclonal antibody (BioLegend, San Diego, CA. USA). Stains were visualized with 3,3′-diaminobenzidine and hematoxylin counterstain and interpreted by a board-certified pathologist \[[@R24]\]. The intensity of tissue infiltration by Tregs (FOXP3^+^) was expressed as number of positive cells per microscopic 40x high-power field evaluated on an Olympus BX41 light microscope (Leica Biosystems, Wetzlar, Germany).
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